Inclusion Criteria:

- Biopsy confirmed locally recurrent prostate adenocarcinoma > 30months after the
completion of radiotherapy by a stereotactic transperineal biopsy

- Staging T2 weighted, DWI and DCE-MRI that demonstrates solitary recurrence confined
to prostate, and correlates with stereotactic transperineal biopsy

- Low or intermediate risk prostate cancer at initial diagnosis that is defined as
stages T1-T2cN0, Gleason score 2-7 and PSA < 20ng/mL

- American Urological Association Symptom Index Score (ie. IPSS) < 15

- Baseline (post radiotherapy) serum PSA < 10 ng/mL

- Prostate volume as measured by transrectal ultrasound (TRUS) < 50cc

- ECOG performance status 0-1

Exclusion Criteria:

- Prior radiotherapy to the prostate that exceeded 78Gy (2Gy fractions)

- Any of the following prior therapies: transurethral resection of the prostate (TURP),
radionuclide (permanent or temporary implantation) prostate brachytherapy,
prostatectomy or prostatic cryosurgery, HIFU (hi-intensity focused ultrasound),
bilateral orchiectomy, chemotherapy for prostatic carcinoma

- Evidence of castrate resistance (defined as PSA > 3 ng/mL while testosterone is < 1.7
nmol/L). Patients could have been on combined androgen blockade with initial
radiotherapy but are excluded if this was started due to PSA progression.